Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | aldehyde dehydrogenase 1 family, member A1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Succinate-semialdehyde dehydrogenase [NADP+] dependent (SSDH) GabD1 | aldehyde dehydrogenase 1 family, member A1 | 501 aa | 456 aa | 33.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | Steroid hormone receptor family member cnr14 homolog | 0.0007 | 0 | 0.5 |
Entamoeba histolytica | tyrosyl-DNA phosphodiesterase, putative | 0.0197 | 1 | 0.5 |
Echinococcus granulosus | tyrosyl DNA phosphodiesterase 1 | 0.0197 | 1 | 1 |
Echinococcus multilocularis | aldehyde dehydrogenase, mitochondrial | 0.0073 | 0.3476 | 0.3476 |
Onchocerca volvulus | Protein ultraspiracle homolog | 0.0007 | 0 | 0.5 |
Trypanosoma brucei | tyrosyl-DNA Phosphodiesterase (Tdp1), putative | 0.0197 | 1 | 0.5 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0073 | 0.3476 | 0.5 |
Mycobacterium tuberculosis | Probable aldehyde dehydrogenase | 0.0073 | 0.3476 | 0.5 |
Schistosoma mansoni | tyrosyl-DNA phosphodiesterase | 0.0197 | 1 | 1 |
Loa Loa (eye worm) | tyrosyl-DNA phosphodiesterase | 0.0197 | 1 | 1 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0073 | 0.3476 | 0.5 |
Echinococcus multilocularis | tyrosyl DNA phosphodiesterase 1 | 0.0197 | 1 | 1 |
Echinococcus granulosus | aldehyde dehydrogenase mitochondrial | 0.0073 | 0.3476 | 0.3476 |
Echinococcus multilocularis | retinoic acid receptor rxr beta a retinoic acid receptor rxr alpha a retinoic acid receptor rxr alpha | 0.0101 | 0.4934 | 0.4934 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0073 | 0.3476 | 0.3476 |
Onchocerca volvulus | 0.0007 | 0 | 0.5 | |
Echinococcus multilocularis | transcription factor Dp 1 | 0.0114 | 0.5622 | 0.5622 |
Onchocerca volvulus | Bile acid receptor homolog | 0.0007 | 0 | 0.5 |
Leishmania major | tyrosyl-DNA phosphodiesterase 1 | 0.0197 | 1 | 1 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0073 | 0.3476 | 0.5 |
Schistosoma mansoni | retinoic acid receptor RXR | 0.0105 | 0.5143 | 0.5143 |
Trypanosoma cruzi | tyrosyl-DNA Phosphodiesterase (Tdp1), putative | 0.0197 | 1 | 0.5 |
Echinococcus granulosus | transcription factor Dp 1 | 0.0114 | 0.5622 | 0.5622 |
Toxoplasma gondii | aldehyde dehydrogenase | 0.0073 | 0.3476 | 0.5 |
Echinococcus granulosus | retinoic acid receptor rxr beta a | 0.0105 | 0.5143 | 0.5143 |
Trypanosoma cruzi | tyrosyl-DNA Phosphodiesterase (Tdp1), putative | 0.0197 | 1 | 0.5 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0073 | 0.3476 | 0.3476 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 8.9125 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 997 ] | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 1467, 2100, 2112, 1473, 1466 ] | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.